Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: What works and what is worthless, part I

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 249-257

  Moyad, Mark A ^a   Barada, James H ^b   Lue, Tom F ^c   Mulhall, John P ^d   Goldstein, Irwin ^e   Fawzy, Ahmed ^f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 DEHYDROEPIANDROSTERONE; ASCORBIC ACID; ECHINACEA EXTRACT; EPHEDRA EXTRACT; EPIANDROSTERONE; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; PLACEBO; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VALERIAN; VARDENAFIL; YOHIMBINE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; ELECTROACUPUNCTURE; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; HEALTH; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEAT; HUMAN; LASER; LIFESTYLE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; UROLOGY; VITAMIN SUPPLEMENTATION;

ADULT; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS; IMPOTENCE; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 2342525947     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.01.006     Document Type: Review

References (83)

1. Anderson J.W. Diet first, then medication for hypercholesterolemia. JAMA. 290:(4):2003;531-533
2. Ernst N.D., Cleeman J.I. National cholesterol education program keeps a priority on lifestyle modification to decrease cardiovascular disease risk. Curr Opin Lipidol. 13:2002;69-73
3. Lue T.F. Erectile dysfunction. N Engl J Med. 342:(24):2000;1802-1813
4. Feldman H.A., Johannes C.B., Derby C.A., et al. Erectile dysfunction and cardiovascular risk: prospective results from the Massachusetts Male Aging Study. Prev Med. 30:(4):2000;328-338
5. Michal V. Arterial disease as a cause of impotence. Clin Endocrinol Metab. 11:(3):1982;725-748
6. Agarwal A., Jain D.C. Male sexual dysfunction after stroke. J Assoc Physicians India. 37:(8):1989;505-507
7. Derby C.A., Mohr B.A., Goldstein I., et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 56:(2):2000;302-306
8. Levine S.B. Erectile dysfunction: why drug therapy isn't always enough. Cleve Clin J Med. 70:(3):2003;241-246
9. Nash I.S., Mosca L., Blumenthal R.S., et al. Contemporary awareness and understanding of cholesterol as a risk factor. Results of an American Heart Association National Survey. Arch Intern Med. 163:2003;1597-1600
10. Navas-Nacher E.L., Colangelo L., Beam C., Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med. 134:2001;433-439
11. Stamler J., Daviglus M.L., Garside D.B., et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 284:2000;311-318
12. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 151:(1):1994;54-61
13. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 163:(2):2000;460-463
14. Bacon C.G., Mittleman M.A., Kawachi I., et al. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-up Study. Ann Intern Med. 139:(3):2003;161-168
15. Solomon H., Man J.W., Wierzbicki A.S., Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol. 91:2003;230-231
16. Walczak M.K., Lokhandwala N., Hodge M.B., Guay A.T. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 5:(6):2002;19-24
17. Kongkanand A. Prevalence of erectile dysfunction in Thailand. Thai Erectile Dysfunction Epidemiological Study Group. Int J Androl. 23:(Suppl 2):2000;77-80
18. Chung W.S., Sohn J.H., Park Y.Y. Is obesity an underlying factor in erectile dysfunction? Eur Urol. 36:(1):1999;68-70
19. Al Helali N.S., Abolfotouh M.A., Ghanem H.M. Pattern of erectile dysfunction in Jeddah city. Saudi Med J. 22:(1):2001;34-38
20. Aydin S., Unal D., Erol H., et al. Multicentral clinical evaluation of the aetiology of erectile dysfunction: a survey report. Int Urol Nephrol. 32:(4):2001;699-703
21. Martin-Morales A., Sanchez-Cruz J.J., Saenz de Tejada I., Rodriguez-Vela L., Jimenez-Cruz J.F., Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfunction Erectil Masculina Study. J Urol. 166:(2):2001;569-574
22. Vaaler S., Lovkvist H., Svendsen K.O., Furuseth K. Erectile dysfunction among Norwegian men over 40 years of age. Tidsskr Nor Laegeforen. 121:(1):2001;28-32
23. Mak R., De Backer G., Kornitzer M., De Meyer J.M. Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. Eur Urol. 41:(2):2002;132-138
24. Blanker M.H., Bohnen A.M., Groeneveld F.P., et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc. 49:(4):2001;436-442
25. Moreira E.D. Jr., Bestane W.J., Bartolo E.B., Fittipaldi J.A. Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil. Sao Paulo Med J. 120:(2):2002;49-54
26. Nicolosi A., Moreira E.D. Jr., Shirai M., Bin Mohd Tambi M.I., Glasser D.B. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 61:(1):2003;201-206
27. Kolodny L. Erectile function and vascular disease: what is the connection? Postgrad Med. 114:(4):2003;30-40
28. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 280:(18):1998;1569-1575
29. Crocetti E., Crotti N., Feltrin A., et al. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer. 34:(3):1998;324-328
30. MacLennan A.H., Wilson D.H., Taylor A.W. Prevalence and cost of alternative in Australia. Lancet. 347:(9001):1996;569-573
31. Blendon R.J., DesRoches C.M., Benson J.M., et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med. 161:(6):2001;805-810
32. Yesalis C.E. Medical, legal, and societal implications of androstenedione use. JAMA. 281:(21):1999;2043-2044
33. Morris C.A., Avorn J. Internet marketing of herbal products. JAMA. 290:(11):2003;1505-1509
34. DeAngelis C.D., Fontanarosa P.B. Drugs alias dietary supplements. JAMA. 290:(11):2003;1519-1520
35. Anderson J.W., Johnstone B.M., Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 333:(5):1995;276-282
36. Moyad M.A. Rules to follow before advising patients on dietary supplements/alternative medicine. Part I. Urol Nurs. 22:(2):2002;99-110
37. Harkey M.R., Henderson G.L., Gershwin M.E., et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 73:(6):2001;1101-1106
38. Parasrampuria J., Schwartz K., Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 280:(18):1998;1565
39. Silverman E. Herbal sex pills thrive on fantasy more than fact. Newark Star-Ledger. January 30, 2000.
40. Sharlip I. "Herbal sex pills thrive on fantasy more than fact" (headline in the Newark Star-Ledger, January 30, 2000). International Society for Sexual and Impotence Research newsbulletin. December 2001;7:17.
41. Markowitz J.S., Donovan J.L., DeVane C.L., et al. Effect of St. John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 290:(11):2003;1500-1504
42. Ang-Lee M.K., Moss J., Yuan C.-S. Herbal medicines and perioperative care. JAMA. 286:(2):2001;208-216
43. Carnes C.A., Chung M.K., Nakayama T., et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 89:(6):2001;E32-E38
44. Korantzopoulos P., Kolettis T., Siogas K., Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit. 9:(9):2003;RA225-RA229
45. Byers T. What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer J Clin. 49:(6):1999;353-361
46. Pepper O.H.P. A note on placebo. Am J Pharm. 117:1945;409-412
47. Beecher H.K. The powerful placebo. JAMA. 159:1955;1602-1606
48. Turner J.A., Deyo R.A., Loeser J.D., et al. The importance of placebo effects in pain treatment and research. JAMA. 271:(20):1994;1609-1614
49. Hrobjartsson A., Gotzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 344:(21):2001;1594-1602
50. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:(7):1999;498-511
51. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:(20):1995;1301-1307
52. Schrott H., Fereshetian A.G., Knopp R.H., et al. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J Cardiovasc Pharmacol Ther. 3:(2):1998;119-124
53. Gentile S., Turco S., Guarino G., et al. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab. 2:(6):2000;355-362
54. Ravin P., Bidstrup M., Wasnich R.D., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med. 131:(12):1999;935-942
55. McClellan K.J., Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 57:(1):1999;111-126
56. Whiting D.A., Jacobsen C. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Derm. 31:(11):1992;800-804
57. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA. 270:(1):1993;83-90
58. Benet A.E., Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 22:(4):1995;699-709
59. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:(20):1998;1397-1404
60. Meuleman E., Cuzin B., Opsomer R.J., et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. 87:(1):2001;75-81
61. Montorsi F., McDermott T.E., Morgan R., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 53:(5):1999;1011-1018
62. Dula E., Buttler S., Perdok R., Agre K. Efficacy and safety of apomorphine SL vs placebo for erectile dysfunction in patients with coronary artery disease. J Urol. 163:2000;200. [abstract: 889]
63. Moyad M.A. The placebo effect and randomized trials: analysis of conventional medicine. Urol Clin North Am. 29:(1):2002;125-133
64. Moyad M.A. The placebo effect and randomized trials: analysis of alternative medicine. Urol Clin North Am. 29:(1):2002;135-155
65. Moyad M.A. The ABCs of nutrition and supplements for prostate cancer. 2003;JW Edwards Publishing, Ann Arbor (MI)
66. Shifren J.L., Braunstein G.D., Simon J.A., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 343:(10):2000;682-688
67. Guzick D.S., Hoeger K. Sex, hormones, and hysterectomies. N Engl J Med. 343:(10):2000;730-731
68. Ernst E. A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust. 174:(2):2001;88-92
69. Avants S.K., Margolin A., Holford T.R., Kosten T.R. A randomized controlled trial of auricular acupuncture for cocaine dependence. Arch Intern Med. 160:(15):2000;2305-2312
70. Moyad M.A., Hathaway S., Ni H.-S. Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research. Semin Urol Oncol. 17:(2):1999;103-110
71. NIH Consensus Development Panel on Acupuncture. Acupuncture. JAMA. 280:(17):1998;1518-1524
72. Morey S.S. NIH issues consensus statement on acupuncture. Am Fam Physician. 57:(10):1998;2545-2546
73. Yamashita H., Tsukayama H., Tanno Y., et al. Adverse effects related to acupuncture. JAMA. 280:(18):1998;1563-1564
74. Norheim A.J., Fonnebo V. Adverse effects of acupuncture. Lancet. 345:(8964):1995;1576
75. Rosted P. The use of acupuncture in dentistry: a review of the scientific validity of published papers. Oral Dis. 4:(2):1998;100-104
76. Peacher W.G. Adverse reactions, contraindications, and complications of acupuncture and moxibustion. Am J Chin Med. 3:(1):1975;35-46
77. Engelhardt P.F., Daha K., Zils T., Pfluger H. Acupuncture in the treatment of erectile dysfunction: first results of a placebo controlled prospective study. J Urol. 163:2000;203. [abstract 902]
78. Hammar M., Frisk J., Grimas O., et al. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol. 161:(3):1999;853-856
79. Kronenberg F., Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized controlled trials. Ann Intern Med. 137:(10):2002;805-813
80. Quella S.K., Loprinzi C.L., Barton D.L., et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol. 18:(5):2000;1068-1074
81. Barton D.L., Loprinzi C.L., Quella S.K., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 16:(2):1998;495-500
82. Tice J.A., Ettinger B., Ensrud K., Wallace R., Blackwell T., Cummings S.R. Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) Study. A randomized controlled trial. JAMA. 290:(2):2003;207-214
83. Johnstone P.A.S., Bloom T.L., Niemtzow R.C., et al. A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms. J Urol. 169:(March):2003;1037-1103